Journal Mobile Options
Table of Contents
Vol. 23, No. 3, 2002
Issue release date: May–June 2002 (September 2002)
Tumor Biol 2002;23:154–169

The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure

O’Brien T.J. · Beard J.B. · Underwood L.J. · Shigemasa K.
aDepartment of Obstetrics and Gynecology, and bDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, Ark., USA; cDepartment of Obstetrics and Gynecology, Hiroshima University School of Medicine, Hiroshima, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


CA 125 is a well-established marker for patients diagnosed with ovarian carcinoma. It is clearly elaborated in serous cystadenocarcinomas and less likely to be expressed in mucinous tumors. It has been 20 years since CA 125 was first recognized and it is only in recent years (the past 2) that some progress has been made toward cloning the gene, providing the basis for an understanding of the functional role of this molecule in embryonic development and neoplastic transformation. It is now clear that CA 125 is a large glycoprotein which is anchored to the epithelium by a transmembrane domain and is released into the extracellular space by enzymatic cleavage. Here, we describe a further major extension to the glycosylated extracellular amino terminal domain of this molecule. These additional data in association with our previous understanding of this molecule will provide the basis for our ability to understand the physiologic function of this molecule in biologic development and pathologic transformation.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RC, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331–1337.
  2. Yin TWT, Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen. Identification as a new mucin (MUC16). J Biol Chem 2001;276:27371–27375.
  3. O’Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L: The CA125 gene: An extracellular superstructure dominated by repeat sequences. Tumor Biol 2001;22:348–366.
  4. Hovig E, Rye PD, Warren DJ, Nustad K: CA 125: The end of the beginning. Tumor Biol 2001;22:345–347.
  5. Benedet JL, Bender H, Jones H 3rd, Ngan HYS, Pecorelli S: FIGO staging classifications and clinical practice guidelines in the management of gynecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209–262.
  6. Scully RE: Tumors of the Ovary and Maldeveloped Gonads, ser 2. Washington, Armed Forces Institute of Pathology, 1979, pp 53–151.
  7. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, Korourian S, Baker VV, O’Brien TJ: P16 overexpression: A potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 1997;4:95–102.
  8. Shigemasa K, Hu C, West CM, Moon SH, Parham GP, Parmley TH, Korourian S, Baker VV, O’Brien TJ: P21: A monitor of p53 dysfunction in ovarian neoplasia. Int J Gynecol Cancer 1997;7:296–303.
  9. Shigemasa K, Tanimoto H, Parham GP, Parmley TH, Ohama K, O’Brien TJ: Cyclin D1 overexpression and p53 mutation status in epithelial ovarian cancer. J Soc Gynecol Investig 1999;6:102–108.
  10. Nustad K, Onsrud M, Jansson B, Warren D: CA125 – Epitopes and molecular size. Int J Biol Markers 1998;13/4:196–199.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50